Prostate Cancer Trial, Recruiting NCT07115914 Sponsor: University of Chicago Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT07115914
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who were assigned male at birth and are 18 years of age or older.
  • People who are able to understand the study information and sign a written consent form.
  • People who have been diagnosed with prostate cancer confirmed through a specific type of biopsy procedure, where tissue samples were taken both randomly across the prostate and from targeted areas using MRI imaging — and that biopsy must have been done within the past year.
  • People who have decided to have focal therapy (a treatment that targets only part of the prostate) and have a procedure scheduled within 6 months of joining the study.
  • People whose prostate cancer has been confirmed as non-metastatic (has not spread to other parts of the body) through recent scans such as a CT scan, bone scan, or PSMA-PET scan taken within the past 6 months — this applies particularly to those with intermediate or high-risk prostate cancer.
  • People whose general health and physical functioning meets a minimum level as assessed by a standard medical scoring system (confirm with trial site for specific score thresholds).
  • People who are considered medically suitable to undergo general anaesthesia and the focal therapy procedure, including being able to tolerate the required body positioning during surgery, as determined by the treating doctor.

Who may not be able to join:

  • People who have received prostate cancer treatments — such as chemotherapy, hormone therapy, radiation, biological therapy, or surgery — within the past 12 months. (Note: People who received radiation or hormone therapy more than 12 months before a recurrence diagnosis may still be considered eligible — confirm with trial site.)
  • People whose prostate cancer has spread locally beyond the prostate, to nearby lymph nodes, or to other parts of the body.
  • People who are unable to have a pelvic MRI scan, for example due to severe claustrophobia, a permanent cardiac pacemaker, certain metal implants in the body, or an allergy or medical reason preventing the use of the contrast dye used in MRI.
  • People who have a serious or uncontrolled ongoing illness that is significantly affecting their health.
  • People whom the treating doctor considers unsuitable for the study, or who are unlikely to be able to follow the study requirements.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Abhinav Sidana, MD, University of Chicago

Phone: (773) 702-4400

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
19 November 2025
Est. completion
1 August 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Determine if adding PSMA-PET scan to MRI will improve cancer detection

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov